ZNTL
ZentalisANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Bull case rests on the late-2027 liquidity runway plus active ASPENOVA and broader pipeline execution, and on the possibility that DENALI Part 2 topline supports an accelerated-approval path if the data are positive [#10-Q-2026-05-12][#10-K-2026-03-26].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +6.9.
What can break
ASPENOVA and other pipeline programs remain execution-sensitive, with trial, enrollment, or regulatory setbacks possible.
Momentum
94
Value
41
Sentiment
60
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.30 · Bull $7.00 · Bear $2.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-28 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $5.31
Why
Momentum94 · Δ7d +6.9
Value41 · Δ7d +0.1
Sentiment60 · Δ7d -9.5
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
94
34% active weight
Current posture
7d trendFlat
Δ7d
+6.9
Δ21d
-2.7
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
60
33% active weight
Current posture
7d trendSoftening
Δ7d
-9.5
Δ21d
+14.4
Why this grade
Composite grade A. Momentum 93.7 / Value 41.1 / Sentiment 60.4
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$283.32M
Beta
1.71
Shares Out
72.25M
P/E (TTM) · Derived
-1.7
P/S (TTM)
3.68
P/FCF (TTM) · Derived
-2.10
Rev YoY
-100.0%
EPS YoY
+34.5%
Gross Margin
-
Op Margin
-615.2%
Net Debt
-$371.08M
Current Ratio
7.76
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology